

NCI Workshop on Cell-based Immunotherapy for Solid Tumors
Dec 10-11, 2018 | 6700B Rockledge Drive, Bethesda, MD
MEETING AGENDA

DECEMBER 10, 2018

9:00 AM Welcome and Opening Remarks

Ned Sharpless, Director, National Cancer Institute

9:15 AM Goals of the Workshop

James Doroshow, Director, Division of Cancer Treatment and Diagnosis, NCI

SESSION 1 - CLINICAL PERSPECTIVE

9:25 AM Keynote Presentation - *Bit by Bit: Putting It Together*

Malcolm Brenner, Baylor College of Medicine

9:45 AM *Targeting Unique Somatic Mutations for the Immunotherapy of Solid Epithelial Cancers*

Steven Rosenberg, National Cancer Institute

10:05 AM *TCR Gene Therapy for Epithelial Cancers*

Christian Hinrichs, National Cancer Institute

10:25 AM COFFEE BREAK

10:40 AM *Successes and Challenges with CAR-T Cell Therapy for Hematologic Malignancies*

Terry Fry, University of Colorado, Denver

11:00 AM *Insights into Toxicities of CD19 CAR-T Cells*

Cameron Turtle, Fred Hutchinson Cancer Research Center and University of Washington

11:20 AM *Opportunities and Challenges in Developing CAR-T Cells for Solid Tumors*

Marcela Maus, Massachusetts General Hospital and Harvard University

11:40 AM PANEL DISCUSSION, TERRY FRY

12:10 PM LUNCH

SESSION 2 - STATE OF THE SCIENCE

1:10 PM *CAR-T Cell Therapy for Solid Tumors: A Work in Progress*

Steven Albelda, University of Pennsylvania

1:30 PM *Target antigen selection for solid tumor CAR T-cell therapy*

Stephen Gottschalk, St. Jude Children's Research Hospital

1:50 PM *An NIH Intramural/Extramural Collaboration to Target Renal Cell Carcinoma with TCR Transduced Autologous T Cells*

Michael Nishimura, Loyola University of Chicago

2:10 PM COFFEE BREAK

2:25 PM *Moving CARs Forward: Next Generation CAR-T Cells*

Renier Brentjens, Memorial Sloan Kettering Cancer Center

2:55 PM *Switchable CARs: Targeting More Than One Antigen*

Travis Young, California Institute for Biomedical Research

3:15 PM *Engineered Human Pluripotent Stem Cell-derived NK Cells with Improved Anti-Tumor Activity*

Dan Kaufman, University of California San Diego

3:35 AM PANEL DISCUSSION, STEVEN ALBELDA

DECEMBER 11, 2018

8:45 AM Recap of Day 1 and Goals for Day 2

Rose Aurigemma, National Cancer Institute

SESSION 3 - TECHNOLOGICAL CHALLENGES FOR CELL THERAPY

9:00 AM *Overview of Steps in Manufacturing Genetically Engineered T Cells*

David Stroncek, NIH Clinical Center

9:20 AM *Replicating Virus Testing in Integrating Vectors: So Far So Good*

Kenneth Cornetta, Indiana University

9:40 AM *Genome Editing in the Clinic for Cancer Indications: Status of the Field and General Considerations for IND-enabling Safety and Efficacy Studies*

Fyodor Urnov, Altius Institute for Biomedical Sciences

10:00 AM COFFEE BREAK

10:15 AM *Challenges of Expanding Tumor Infiltrating Lymphocytes (TIL) from Solid Tumors*

Chantale Bernatchez, MD Anderson Cancer Center

10:35 AM *Challenges in CAR-T Cell Manufacturing*

Isabelle Riviere, Memorial Sloan Kettering Cancer Center

10:55 AM *Cellular Product Release and Potency Testing*

Lisa Butterfield, Parker Institute and University of California San Francisco

11:15 AM *CAR-T Cell Therapy: Going Beyond the Test Drive*

Nirali Shah, National Cancer Institute

11:35 AM PANEL DISCUSSION, CHANTALE BERNATCHEZ

12:05 PM LUNCH BREAK

SESSION 4 - FDA AND INDUSTRY PERSPECTIVE

1:00 PM *Cell-based Immunotherapy for Solid Tumors: US FDA Regulatory Perspectives*

Ke Liu, Food and Drug Administration

1:20 PM *Regulatory Considerations for Cell and Gene Therapy Manufacturing*

Thomas Finn, Food and Drug Administration

1:40 PM *Cell-based Immunotherapy for Solid Tumors: The Role of Small Business*

Jake Reder, Celdara Medical and Giesel School of Medicine at Dartmouth

2:00 PM *Partnering with the NCI: Intellectual Property Issues*

Jason Cristofaro, National Cancer Institute

2:20 PM PANEL DISCUSSION